Glaxosmithkline Pharmaceuticals Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|
| Revenue | 1,036.93 | 846.85 | 943.14 |
| Operating Expense | 681.10 | 581.58 | 655.56 |
| Net Profit | 248.69 | 181.65 | 193.08 |
| Net Profit Margin | 23.98 | 21.45 | 20.47 |
| Earning Per Share | 14.45 | 10.72 | 11.29 |
| EBIDTA | 363.28 | 261.76 | 273.11 |
| Effective Tax Rate | 27.39 | 23.87 | 21.27 |
| Particulars | Sep 2024 |
|---|---|
| Revenue | 1036.93 |
| Operating Expense | 681.10 |
| Net Profit | 248.69 |
| Net Profit Margin | 23.98 |
| Earning Per Share | 14.45 |
| EBIDTA | 363.28 |
| Effective Tax Rate | 27.39 |
Invest in Glaxosmithkline Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Total Revenue Annual | 3,407.25 | 3,216.34 | 3,217.51 |
| Operating Expenses Annual | 2,506.60 | 2,416.92 | 2,461.68 |
| Operating Profit Annual | 880.51 | 903.02 | 2,157.57 |
| Interest Annual | 1.80 | 1.81 | 1.99 |
| Depreciation | 59.14 | 56.07 | 43.96 |
| Net Profit Annual | 584.69 | 604.71 | 376.58 |
| Tax Annual | 224.35 | 227.69 | 396.87 |
| Particulars | Mar 2024 |
|---|---|
| Total Revenue Annual | 3,407.25 |
| Operating Expenses Annual | 2,506.60 |
| Operating Profit Annual | 880.51 |
| Interest Annual | 1.80 |
| Depreciation | 59.14 |
| Net Profit Annual | 584.69 |
| Tax Annual | 224.35 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Cash Flow at the Beginning | 29.74 | 280.79 | 404.90 |
| Cash Flow from Operations | 578.94 | 487.94 | 819.79 |
| Cash Flow from Investing | 14.97 | 805.19 | -419.66 |
| Cash Flow from Financing | -561.50 | -1,544.18 | -524.24 |
| Cash Flow at the End | 62.15 | 29.74 | 280.79 |
| Particulars | Mar 2024 |
|---|---|
| Cash Flow at the Beginning | 29.74 |
| Cash Flow from Operations | 578.94 |
| Cash Flow from Investing | 14.97 |
| Cash Flow from Financing | -561.50 |
| Cash Flow at the End | 62.15 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| PBDIT Margin (%) | 28.60 | 28.08 | 25.83 |
| PBIT Margin (%) | 26.55 | 26.03 | 23.71 |
| PBT Margin (%) | 11.80 | 11.65 | 11.79 |
| Net PROFIT Margin (%) | 17.16 | 18.90 | 52.54 |
| Return On Networth / Equity (%) | 36.83 | 27.43 | 80.45 |
| Return On Networth /Employed (%) | 44.44 | 33.60 | 32.11 |
| Return On Assets (%) | 28.66 | 24.38 | 70.93 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 1.67 | 1.29 | 1.35 |
| Particulars | Mar 2024 |
|---|---|
| PBDIT Margin (%) | 28.60 |
| PBIT Margin (%) | 26.55 |
| PBT Margin (%) | 11.80 |
| Net PROFIT Margin (%) | 17.16 |
| Return On Networth / Equity (%) | 36.83 |
| Return On Networth /Employed (%) | 44.44 |
| Return On Assets (%) | 28.66 |
| Total Debt / Equity (X) | 0.01 |
| Asset Turnover Ratio (%) | 1.67 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
| Fixed Assets Annual | 320.36 | 328.90 | 329.44 |
| Total Current Assets Annual | 2,765.84 | 2,466.72 | 3,670.71 |
| Non Current Assets Annual | 781.96 | 860.98 | 951.89 |
| Total Shareholders Funds Annual | 1,784.09 | 1,753.00 | 2,677.62 |
| Total Assets Annual | 3,547.80 | 3,327.70 | 4,622.60 |
| Particulars | Mar 2024 |
|---|---|
| Fixed Assets Annual | 320.36 |
| Total Current Assets Annual | 2,765.84 |
| Non Current Assets Annual | 781.96 |
| Total Shareholders Funds Annual | 1,784.09 |
| Total Assets Annual | 3,547.80 |
EPS (INR)
Expected
14.90
Reported
14.67
Surprise
-1.54%
Jun 2024
EPS beaten by -1.54%
Mar 2024
EPS beaten by 0.00%
Dec 2023
EPS beaten by -0.96%
